Skip to main content
See every side of every news story
Get Started
SubscribeLogin
Published • loading... • Updated

Quotient Sciences extends commercial manufacturing partnership

Summary by European Pharmaceutical Manufacturer
Quotient Sciences has extended commercial supply partnership with Ipsen to manufacture a treatment for Fibrodysplasia Ossificans Progressiva (FOP), an ultra-rare disease affecting fewer than 1,000 people worldwide.
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.Cross Cancel Icon

1 Articles

European Pharmaceutical ManufacturerEuropean Pharmaceutical Manufacturer

Quotient Sciences extends commercial manufacturing partnership

Quotient Sciences has extended commercial supply partnership with Ipsen to manufacture a treatment for Fibrodysplasia Ossificans Progressiva (FOP), an ultra-rare disease affecting fewer than 1,000 people worldwide.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

European Pharmaceutical Manufacturer broke the news in on Thursday, February 26, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)
Blindspot Title And Logo
Stories disproportionately reported by the Left or the Right

Similar News Topics

Milton Keynes icon

Milton Keynes

News
Feed Dots Icon
For You
Search Icon
SearchBlindspot LogoBlindspotLocal